679 related articles for article (PubMed ID: 8978408)
1. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
2. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
Shi XB; Bodner SM; deVere White RW; Gumerlock PH
Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
[TBL] [Abstract][Full Text] [Related]
3. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis.
Bosari S; Marchetti A; Buttitta F; Graziani D; Borsani G; Loda M; Bevilacqua G; Coggi G
Diagn Mol Pathol; 1995 Dec; 4(4):249-55. PubMed ID: 8634780
[TBL] [Abstract][Full Text] [Related]
4. p53 in prostate cancer: frequent expressed transition mutations.
Chi SG; deVere White RW; Meyers FJ; Siders DB; Lee F; Gumerlock PH
J Natl Cancer Inst; 1994 Jun; 86(12):926-33. PubMed ID: 7515114
[TBL] [Abstract][Full Text] [Related]
5. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
6. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
9. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor gene p53 mutations in human prostate cancer.
Kubota Y; Shuin T; Uemura H; Fujinami K; Miyamoto H; Torigoe S; Dobashi Y; Kitamura H; Iwasaki Y; Danenberg K
Prostate; 1995 Jul; 27(1):18-24. PubMed ID: 7603913
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer.
Calzolari A; Chiarelli I; Bianchi S; Messerini L; Gallo O; Porfirio B; Mattiuz PL
Am J Clin Pathol; 1997 Jan; 107(1):7-11. PubMed ID: 8980360
[TBL] [Abstract][Full Text] [Related]
12. A novel p53 mutation hotspot at codon 132 (AAG-->AGG) in human renal cancer.
Dahiya R; Deng G; Selph C; Carroll P; Presti J
Biochem Mol Biol Int; 1998 Feb; 44(2):407-15. PubMed ID: 9530523
[TBL] [Abstract][Full Text] [Related]
13. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors.
Soong R; Iacopetta BJ
Mod Pathol; 1997 Mar; 10(3):252-8. PubMed ID: 9071734
[TBL] [Abstract][Full Text] [Related]
14. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
16. p53 gene alterations in human prostate carcinoma.
Effert PJ; McCoy RH; Walther PJ; Liu ET
J Urol; 1993 Jul; 150(1):257-61. PubMed ID: 8510267
[TBL] [Abstract][Full Text] [Related]
17. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
18. Effect of non-tumor cell contamination on detection of p53 gene mutations in human gastric cancer cells by polymerase chain reaction single-strand conformation polymorphism analysis.
Hong WS; Hong SI; Lee DS; Son Y
Korean J Intern Med; 1994 Jan; 9(1):20-4. PubMed ID: 8038143
[TBL] [Abstract][Full Text] [Related]
19. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis.
Rakozy C; Grignon DJ; Li Y; Gheiler E; Gururajanna B; Pontes JE; Sakr W; Wood DP; Sarkar FH
Pathol Res Pract; 1999; 195(3):129-35. PubMed ID: 10220791
[TBL] [Abstract][Full Text] [Related]
20. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
